A series of free presentations across the state for healthcare providers about pain treatment and opioid misuse is being provided by UAMS AR-IMPACT, a program of the University of Arkansas for Medical Sciences (UAMS).
While the continuing medical education presentations are occurring at locations across Arkansas, all can be viewed remotely via ARIMPACT.UAMS.edu/speakersbureau. The AR-Impact (Improving Multi-disciplinary Pain Care and Treatment) speakers bureau schedule includes:
-Feb. 13, 12 n.n-2 p.m. — UAMS Southwest Regional Campus, Texarkana — Johnathan Goree, MD — “How the Prescription Drug Epidemic Became an Opioid Epidemic: Failure in Upstream Policy and a Call for Downstream Solutions” and “Neuromodulation and Radiofrequency Ablation: Is it the Pain Treatment of the Future?”
-Feb. 27, 12 n.n-2 p.m. — UAMS South Central Regional Campus, Pine Bluff — Johnathan Goree, MD — “Assessment and Evidence-Based Treatment Algorithms for Low Back Pain” and “Complex Regional Pain Syndrome: Diagnosis, Treatment, and Review of Cases”
-March 5, 12 n.n.-2 p.m. — UAMS South Regional Campus, Magnolia — Corey Hayes, PharmD, PhD — “Opioid Tapering” and “Naloxone Formulations, Cost, and When to Talk to Patients”
-April 2, 12:30-2:30 p.m. — UAMS West Regional Campus, Fort Smith — Leah Tobey, PT, DPT — “Alternative Pain Relief and Self-Management with Physical Therapy” and “Tips for the Busy Clinician: 5-Minute Lumbar Exam”
-April 16, 12 n.n.-2 p.m. — UAMS Northeast Regional Campus, Jonesboro — Masil George, MD — “Opioid Free-Success Stories of Effectively Stopping Opioids” and “Managing the Difficult Patient Encounter”
-April 29, 12 n.n.-2 p.m. — UAMS North Central Regional Campus, Batesville — Leah Tobey, PT, DPT, and Masil George, MD — “Opioids and Falls: Is There a Link?” and “Recognizing and Responding to Suffering”
AR-IMPACT was launched through a partnership between UAMS, the Arkansas Medical Society, the Arkansas Academy of Family Medicine, the Arkansas Department of Health, Arkansas State Medical Board, Arkansas Blue Cross and Blue Shield, and the Office of the State Drug Director.